VivoSeq
Nephrology

Renal Transplant

0

Pipeline Programs↗

6

Active Trials↗

6

Companies Involved↗

Renal Transplant is an early-stage landscape with 0 programs across 6 companies. The most active players are Novartis, Astellas, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

92/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalV

Veloxis Pharmaceuticals

0 programs

PreclinicalH

Hikma Pharmaceuticals LLC

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

76

clinical trials

Completed59 · 78%
Terminated5 · 7%
Unknown status5 · 7%
Active, not recruiting3 · 4%
Not yet recruiting2 · 3%
Approved for marketing1 · 1%
Other1 · 1%

Clinical Trials

Trial Activity

76 trials

The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients.
Recruiting·—·Phase 3·NCT04450953·36 enrolled
Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)
Active, not recruiting·—·Phase 3·NCT02490904·132 enrolled
Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XR™
Active, not recruiting·VVanderbilt University Medical Center·Phase 4·NCT04838288·60 enrolled
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Active, not recruiting·—·Phase 1/2·NCT03380962·20 enrolled
The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes
Not yet recruiting·YYonsei University·Phase 4·NCT05719376·302 enrolled
Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant (PART)
Not yet recruiting·UUniversity of British Columbia·N/A·NCT06802822·96 enrolled
A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)
Completed·Astellas logoAstellas·N/A·NCT02147938·578 enrolled
A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)
Completed·IIrmandade Santa Casa de Misericórdia de Porto Alegre·Phase 4·NCT01822483·100 enrolled
A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.
Completed·Novartis logoNovartis·Phase 4·NCT00738257·126 enrolled
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
Completed·Novartis logoNovartis·Phase 3·NCT00658320·122 enrolled
HLA-Identical Sibling Renal Transplant Tolerance
Completed·NNorthwestern University·N/A·NCT00619528·88 enrolled
Simulect Versus ATG in Sensitized Renal Transplant Patient
Completed·UUniversity Hospital, Toulouse·Phase 4·NCT02377193·60 enrolled
Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day.
Completed·HHospital Universitari de Bellvitge·Phase 4·NCT02961608·25 enrolled
Dual Transversus Abdominis Plane Block in Pediatric Renal Transplant: Effect on Pain Control
Completed·—·N/A·NCT02858622·44 enrolled
Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients
Completed·Novartis logoNovartis·Phase 4·NCT00419926·313 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)